p38-MAPK inhibitor LY2228820, Purity ≥98%

Cat. No.: X23-10-ZQ901

p38-MAPK inhibitor LY2228820, Purity ≥98%

Synonym: 862507-23-1; LY2228820; Ralimetinib mesylate; Ralimetinib dimesylate; LY2228820 diMesylate; Ralimetinib mesilate; p38-MAPK inhibitor

  • MDL: MFCD22572532
  • CAS Number: 862507-23-1
  • Compound CID: 11570805
Product Size
5 mg; 10 mg; 25 mg; 50 mg; 100 mg
Price
Datasheet
MSDS
Properties
Description
LY2228820, soluble in warmed DMSO, warmed water and ethanol, targets the ATP-binding site of the kinase, thereby preventing phosphorylation of downstream substrates. It targets p38α.
Molecular Weight
612.7
Molecular Formula
C24H29FN6.2CH4O3S
Targets
p38α: 7 nM
Form
Lyophilized powder
Purity
≥98%
Solubility
Warmed DMSO: 4 mg/mL (6.52 mM); Warmed water: 91 mg/mL (148.51 mM); Ethanol: 3 mg/mL (4.89 mM)
Identity
Confirmed by NMR/HPLC/MS.
Stability
The product is stable for three years when stored at the recommended temperature in lyophilized powder.
Applications
LY2228820 serves as a research tool in evaluating the inhibition of p38 MAPK alpha and beta isoforms related to inflammatory diseases and cancer.
Storage
Store at -20ºC.
Related Products

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.